Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Genitourinary 1

Conditions

Osteosarcoma 6Lymphoma 4Renal Insufficiency 3Neurotoxicity Syndromes 2Neoplasms 2Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Water Intoxication 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22Thiotepa 20Sirolimus 20Azacitidine 20venetoclax 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × glucarpidase × Clear all
NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

BTG International Inc.

Unknown
1,000 enrolled
GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡